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Dear Editor, 
We have read the paper by Chantepie et al.1 evaluating safety of benadamustine-based conditioning 
prior to autologous stem cell transplantation (ASCT) with great interest. Authors reported 
concerningly high frequency of acute renal failure (27.9%) and high rates of other toxicities observed 
with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen. Shortage of 
carmustine led to replacement of standard BEAM (carmustine, etoposide, cytarabine, melphalan) with 
BeEAM conditioning regimen in our institution as well. High frequency of febrile netropenia and 
increased mortality that we observed prompted us to further compare toxicities and outcomes 
between these two regimens which we report here.   
We retrospectively analysed a cohort of 60 ASCT patients 18 years or older with histologically 
confirmed diagnosis of Non-Hodgkin or Hodgkin lymphoma that received either BEAM (43 patients) 
or BeEAM myeloablative regimen (17 patients) as a part of the ASCT procedure in the period from 
2008 to 2018. Bendamustine doses of 200mg/m2/day were used. Acute kidney injury was defined 
according to KDIGO guidelines as in the paper by Chantepie et al.1 Numerical variables were expressed 
as median and interquartile range (IQR) and were compared between two groups using the Mann-
Whitney-U test. Categorical variables were expressed as percentages and were compared between 
two groups using the Fisher test or Χ2 test where appropriate. Survival analysis was based on the 
Kaplan-Meier method, the Cox-Mantel version of the log-rank test was used to compare survival 
between two groups. P values <0.05 were considered statistically significant. Analyses were done 
using the MedCalc statistical program ver. 18.10 (MedCalc Software bvba, Ostend, Belgium). 
Median age was 51.5 years, a majority of patients had diffuse large B-cell lymphoma (53%). Patients’ 
characteristics and outcomes are shown in the Table. BEAM and BeEAM groups did not differ 
regarding age, gender, diagnosis, baseline estimated creatinine clearance, duration of hospitalization, 
time to neutrophil or platelet recovery (P>0.05 for all comparisons) showing that two regimens were 
comparable in terms of baseline and engraftment characteristics. However, patients receiving 
bendamustine were significantly more likely to develop acute kidney injury (23.5% vs 0% for BeEAM 
vs BEAM, respectively; P=0.005), virtually all experienced febrile neutropenia (100% vs 74% for BeEAM 
vs BEAM, respectively; P=0.025) and were more likely to require intensive-care-unit (ICU) 
management (23.5% vs 0% for BeEAM vs BEAM, respectively; P=0.005). Most worrisome, patients 
receiving bendamustine experienced significantly higher 100-day mortality (17.6% vs 0% for BeEAM 
vs BEAM, respectively; P=0.004) as shown in the Figure. All three deaths observed in the bendamustine 
group were due to septic complications.  
It should be noted that high rates of ICU admission (24%) and renal toxicity (17%) were observed with 
BeEAM by other author groups as well.2 Although limited by small numbers, retrospective design and 
single center experience, our findings complement previously reported results by Chantepie and 
others, and raise serious concerns about safety of benadmustine-based conditioning prior to ASCT. 
We resorted to alternative conditioning regimen based on lomustine (LEAM – lomustine, etoposide, 
cytarabine, melphalan) until additional evidence regarding efficacy/safety of currently available 
regimens, or new treatment options emerge. 
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Table 1: Patient’s characteristics and outcomes in patients receiving BEAM and BeEAM 
myeloablative regimens prior to autologous stem cell transplantation. 
 BEAM BeEAM P value 
Total number 43 17 - 
Age /years 52 IQR (38.5 - 59) 50 IQR (39 - 56) 0.825 
Gender 
Male gender 
Female gender 
24/43 (55.8%) 
19/43 (44.2%) 
8/17 (47.1%) 
9/17 (52.9%) 0.540 
Diagnosis 
DLBCL 
Mantle cell 
Burkitt 
T-NHL 
Indolent B-NHL 
Hodgkin lymphoma 
20/43 (45.2%) 
4/43 (9.5%) 
1/43 (2.4%) 
4/43 (9.5%) 
8/43 (19%) 
6/43 (14.3%) 
10/17 (56.3%) 
2/17 (12.5%) 
0/17 (0%) 
2/17 (12.5%) 
1/17 (6.3%) 
2/17 (12.5%) 0.811 
MDRD estimated 
creatinine clearance 
/mlmin-11.73m-2 88 IQR (75.5 - 100.5) 108 IQR (80 - 122) 0.212 
Duration of 
hospitalization /days 25 IQR (21 - 28.5) 25 IQR (23 - 32) 0.320 
Neutrophil recovery 
/days 10 IQR (9 - 11) 10 IQR (9 - 10) 0.503 
Platelets recovery 
/days 12 IQR (10.5 - 14) 12.5 IQR (11.3 - 16.5) 0.294 
Acute kidney injury 0/43 (0%) 4/17 (23.5%) 0.005* 
Febrile neutropenia 32/43 (74.4%) 17/17 (100%) 0.025* 
Isolated pathogen 27/43 (62.8%) 15/17 (88.2%) 0.053 
Need for intensive 
care unit 0/43 (0%) 4/17 (23.5%) 0.005* 
100-days mortality 0/43 (0%) 3/17 (17.6%) 0.004* 
IQR – interquartile range; numerical variables were compared using the Mann-Whitney U test; 
categorical variables were compared using the Fisher test of Χ2 test where appropriate; mortality 
was analysed using the Cox-Mantel version of the log-rank test. 
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Figure 1: 100-days mortality post autologous stem cell transplantation stratified by the 
myeloablative regimen (BEAM / BeEAM). 
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